ADVAIR HFA 230/21 Rx
Generic Name and Formulations:
Fluticasone propionate 230mcg, salmeterol (as xinafoate) 21mcg; per inh; metered-dose inhaler; CFC-free.
Indications for ADVAIR HFA 230/21:
Maintenance treatment of asthma in patients not adequately controlled on other asthma-controller medications (eg, inhaled corticosteroid) or whose disease severity warrants initiation of 2 maintenance therapies.
See literature. 2 inh twice daily (AM & PM; approx. 12hrs apart). If insufficient response after 2wks, use next higher strength. Max: 2 inh of Advair HFA 230/21 twice daily.
Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures. Concomitant with other forms of salmeterol or formoterol.
Increased risk of asthma-related deaths and hospitalizations. Do not initiate in rapidly or acutely deteriorating asthma. Not for relief of acute bronchospasm. Not for use with other long-acting β2-agonists or for transferring from systemic steroids. Reevaluate periodically. Do not exceed recommended dose. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Hyperglycemia. Hepatic impairment (monitor). Tuberculosis. Untreated infections. Ocular herpes simplex. Eosinophilic conditions. Immunosuppressed. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Monitor potassium, intraocular pressure; bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occurs, discontinue gradually). Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, atazanavir, clarithromycin, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin): not recommended. Caution with other sympathomimetics (except short-acting bronchodilators), during or within 2 weeks of MAOIs, tricyclic antidepressants (increased cardiac effects), K+-depleting diuretics. Antagonized by β-blockers.
Steroid + long-acting beta-2 agonist.
Respiratory tract infection or inflammation, laryngeal spasm or swelling, headache, dizziness, hoarseness, dysphonia, muscle pain, GI upset, candidiasis, menstruation symptoms, intoxication, hangover, paradoxical bronchospasm (discontinue if occurs); rarely: serious asthma episode, asthma-related death.
Inhaler—12g (120 inh)
Sign Up for Free e-newsletters
- 2016 Recommended Immunization Schedule for Adults: What's Changed?
- First Sexually-Transmitted Zika Virus Case Confirmed in Texas
- 2016 Childhood and Adolescent Immunization Schedule Released
- Spiriva Respimat Gains Indication and New Dosage Strength
- To Rx or Not to Rx: Interventions to Improve Antibiotic Prescribing for Uncomplicated Acute RTI
- CDC Guidelines on Preventing Sexual Transmission of Zika Virus Issued
- CDC Updates Interim Zika Virus Guidelines for Pregnant Women and Women of Reproductive Age
- Daklinza Use Expanded to Cover Treatment in More HCV Patients
- Researchers Call for an Alternative Tdap Immunization Strategy for Adolescents
- FDA Announces Large Action Plan in Effort to Reverse the Opioid Epidemic